

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**RainMed**

**Rainmed Medical Limited**  
**潤邁德醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2297)**

**RESIGNATION OF EXECUTIVE DIRECTOR,  
CHIEF FINANCIAL OFFICER AND AUTHORIZED  
REPRESENTATIVE; APPOINTMENT OF NON-EXECUTIVE  
DIRECTOR; AND APPOINTMENT OF  
AUTHORIZED REPRESENTATIVE**

This announcement is made by Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**(1) RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL  
OFFICER AND AUTHORIZED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that Mr. Zhang Liang (張亮) (“**Mr. Zhang**”) has resigned as an executive Director, chief financial officer and authorized representative of the Company (the “**Authorized Representative**”) under Rule 3.05 of the Listing Rules with effect from August 26, 2024 due to his intention to pursue with his other commitments and the need to devote more time for his family. Upon the resignation of Mr. Zhang’s executive Director, chief financial officer and Authorized Representative roles, Mr. Zhang will remain as the joint company secretary of the Company.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhang for his valuable contributions to the Group during his tenure of office as an executive Director and chief financial officer in the Company.

## (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Huo Yunlong (霍雲龍) (“**Dr. Huo**”) has been appointed as a non-executive Director with effect from August 26, 2024.

The biographical details of Dr. Huo are set out below:

Dr. Huo Yunlong (霍雲龍), aged 48, obtained a bachelor degree in fluid machinery and engineering from Tsinghua University (清華大學) in the People’s Republic of China (the “**PRC**”) in July 1999. He further received master degree and doctoral degree in mechanical engineering from National University of Singapore and Washington State University in the United States in June 2004 and July 2005, respectively. Dr. Huo also served his postdoctoral fellow in University of California, Irvine, from August 2005 to June 2006 in the United States. Dr. Huo has profound experience in research and development of mechanical engineering. From July 2006 to December 2012, he served as research assistant professor in Indiana University–Purdue University Indianapolis. From December 2012 to March 2019, he served as Tenure-track associate professor (特聘研究員) for Peking University (北京大學). Since September 2019, he has been appointed and awarded as associate professor of Shanghai Jiao Tong University (上海交通大學). Since August 2023, Dr. Huo has been served as a technology consultant for Hong Kong Rainmed Medical Limited (香港潤邁德醫療有限公司) (“**Rainmed HK**”), a subsidiary of the Company.

Dr. Huo is brother of Mr. Huo Yunfei (霍雲飛), the chairman of the Board, executive Director and chief executive officer of the Company, and Dr. Huo is the cousin of Ms. Gu Yang, our executive Director and vice president of the Company. As of the date of this announcement, Dr. Huo is a substantial shareholder of the Company. He directly holds 420,000 shares of the Company (the “**Shares**”). In addition, Vermilion Bird Limited is owned as to 99.9% by Glowing Fame Limited and 0.1% by Dr. Huo, respectively. Glowing Fame Limited is wholly owned by The Core Trust Company Limited, being the trustee of the Vermilion Bird Trust which is a discretionary trust established Dr. Huo as the settlor and beneficiary. As such, Dr. Huo is deemed to be interested in the 159,934,000 Shares held by Vermilion Bird Limited within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Dr. Huo will hold office until the next annual general meeting of the Company, and will then be eligible for re-election at such meeting. The term of Dr. Huo’s service as a non-executive Director is subject to retirement by rotation and re-election at the annual general meeting of the Company. Dr. Huo will be appointed for a term of three years, which will continue thereafter until terminated by either party giving not less than one month’s prior notice. Dr. Huo has entered into a service contract with the Company for a term of three years commencing on August 26, 2024. He is not entitle to any director’s fee but with HK\$20,000 per month for his service as technology consultant in Rainmed HK, subject to review by the Board from time to time with reference to prevailing market rates for the nature of services rendered.

As at the date of this announcement, save as disclosed above, (i) Dr. Huo does not have any other interests or short positions in any Shares (within the meaning of the SFO); (ii) Dr. Huo has not held any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, and any other major appointments and professional qualifications; (iii) Dr. Huo does not have any other relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Listing Rules); and (iv) Dr. Huo does not hold any other position in the Company and/or its subsidiaries.

Save as disclosed herein, there are no other matters concerning Dr. Huo's appointment that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to extend a warm welcome to Dr. Huo in joining the Company.

### **(3) APPOINTMENT OF AUTHORIZED REPRESENTATIVE**

The Board further announces that, Mr. Huo Yunfei (霍雲飛), the chairman of the Board, executive Director and chief executive officer of the Company, has been appointed as an Authorized Representative, with effect from August 26, 2024.

By Order of the Board  
**Rainmed Medical Limited**  
**Huo Yunfei**

*Chairman of the Board and Executive Director*

Hong Kong, August 26, 2024

*As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui and Ms. Gu Yang as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng as independent non-executive Directors.*